Some time within the next few weeks, VaxGen is expected to announce results of the Phase III trials of its first vaccine candidate based on a bivalent HIV envelope gp120, AIDSVAX B/B. Interpretation of these results will probably not be straightforward and will likely lead to many more unanswered questions. Following is a description of some of the key issues involved.